The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1233
April 24, 2006
View Complete Issue         Table of Contents 2019 
Deferasirox (Exjade): A New Iron Chelator
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Deferasirox (Exjade): A New Iron Chelator
April 24, 2006 (Issue: 1233)
Deferasirox (Exjade - Novartis), an oral chelating agent, recently received accelerated approval from the FDA as an orphan drug for oral treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients >2 years...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Deferasirox (Exjade): A New Iron Chelator
Article code: 1233c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.